MUC2 mRNA detection in peripheral blood and bone marrow of breast cancer patients reveals micrometastasis

Tumor dissemination to distant organ is the cause of death. Therefore there is urgent set up sensitive methods for early dete circulating tumor cells (CTCs) and disse tumor cells (DTCs) in peripheral blood (P bone marrow (BM) specimens of breas patients. We aim to detect MUC2 mRNA cells in PB and BM of breast cancer pati relate this to patient relapse. In this stud tect MUC2 mRNA positive cells (tumor m PB and BM samples were collected f breast cancer patients after operation an adjuvant therapy with 20 PB from healt viduals as negative controls. Chi-squa was used to analyze data. MUC2 mRNA b Real-time PCR was detected in 9 (18% and in 10 (20%) of BM samples and non 2; accepted 28 December 2012 main eed to ion of inated ) and ancer sitive ts Iranian women, with a rough inciden comprising 24.4% of all neoplasms [3] 2006. In breast cancer, both hematogen dissemination of carcinoma cells may tients with small tumors, so breast can systemic disease. Although the detecti axillary lymph nodes is a proven pro ally 20% 30% of ax ; to to derker), m 50 efore indie test using of PB of the mong in BM had a gative s show a recurrence. Micrometastases tectable by classical imaging, can co relapse; therefore, identification of patients with early-stage breast canc nificant impact on deciding treatmen termining prognosis for the patients [4 Different markers have been used detection of bone marrow disseminated and peripheral blood circulating tumo The detection of occult micrometasta (BM) identifies the patients most likely at risk of oping systemic breast cancer relapse. likely benefit from systemic adjuvant th MUC2-positive patients was significanc (P < 0.004) and MUC2-positive shorter disease fre patients in BM sa tudy or deer paancer; it should even be feasible to monito treatment [6]. However, the impact blood or BM still remains controve chemistry currently remains the gold DTC detection, with a sensitivity rang 10 to 1 in 10 leucocytes [5]. Recently shows MUC2 can be a suitable marker tection of micrometastasis in breast ca tients at early stages of cancer.